Foghorn Therapeutics (FHTX) has released an update.
Eli Lilly and Company has chosen FHD-909, an innovative oral medication targeting BRG1, to advance into clinical trials, aiming to treat BRG1 mutated non-small cell lung cancer. With plans to file for Investigational New Drug (IND) status in the second quarter of 2024, this marks a significant step in addressing this specific cancer type. However, investors are cautioned about forward-looking statements which involve risks and uncertainties that could cause actual results to differ from these promising expectations.
For further insights into FHTX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
